[Response of growth hormone to the acute test using GH-releasing factor 1-29 in acromegaly. Comparison in the baseline situation and under treatment with prolonged-action somatostatin].
D000172:Acromegaly / Q000188:drug therapy / Q000503:physiopathology*; D000368:Aged; D003692:Delayed-Action Preparations; D005260:Female; D013006:Growth Hormone / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone / Q000031:analogs & derivatives*; D006801:Humans; D008875:Middle Aged; D015282:Octreotide; D010446:Peptide Fragments; D012636:Secretory Rate / Q000187:drug effects; D017337:Sermorelin; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D003692:Delayed-Action Preparations; D010446:Peptide Fragments; D013004:Somatostatin; D017337:Sermorelin; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D015282:Octreotide
Respuesta de la hormona del crecimiento al test agudo con factor liberador de GH 1-29 en acromegalias. Comparación en situación basal y bajo tratamiento con somatostatina de acción prolongada.